Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754 is registered in ClinicalTrials.gov with Servier Affaires Médicales as lead sponsor.

NCT NCT05876754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05876754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Lead sponsor
Servier Affaires Médicales
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 3, 2023
Completion date
December 1, 2027
Enrollment
299 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma